Bone is the common site for cancer cells division in patients suffering from lung cancer. For the first time scientists have studied the combined effect of application of zoledronic acid (drug given in bone diseases) with calcitonin (calcium regulating hormone). This therapy proved to be more effective than conventional therapy1.
Lung cancer is the common type of malignant tumor2. More than 30% of patients of lung cancer suffer from bone metastasis3. Metastasis of bone usually leads to fracture, pain, paraplegia, spinal compression and hypercalcinemia4.
According to authors:
“Although chemotherapy, molecular targeted therapy, radiotherapy, surgery, analgesia, bisphosphonate therapy have been widely used in lung cancer patients complicated with bone metastasis, current clinical treatment effect of bone metastasis is still limited. Therefore, effective therapeutic methods for bone metastasis of lung cancer are urgently needed.”
Presently the current standard treatment of cancer patients with bone osteoporosis is considered as the pharmacological intervention of bisphosphonates5. Zoledronic acid is a promising new biophosphonate which has been widely used in the treatment of patients with osteoporosis or mixed bone metastases/lesions6. Several studies have verified that zoledronic acid can minimize the risk of skeletal related events in the treatment of cancers dense with bone metastasis7.
It was noted and reported that calcitonin also known as salmon calcitonin can induce apoptosis by inhibiting the activity of parathyroid hormone and the growth of tumor cell8. The calcitonin in osteoporotic fractures’ treatment also reported to considerably minimize the bone mass loss and pain relieve after 1 week of treatment9.
Keeping in mind the above facts, scientists derived and tested a hypothesis that the combined treatment of zoledronic acid and calcitonin may have the good therapeutic effects for lung cancer patients with bone metastases.
For this purpose an experiment was conducted on 100 patients with lung cancer convoluted with osteoporosis and bone metastasis. Patients were divided into 2 groups accordingly. The life quality, bone pain, activity ability, metastatic lesion, serum biochemical indicators of bone metabolism and bone mineral density (BMD) of hip joint, as well as the adverse reactions and skeletal-related events (SREs) were recorded in both two groups1.
It was noted that there was significant improvement in life quality, bone pain, activity ability, and serum biochemical indicators of bone metabolism and BMD of hip joint in the observational group compared with the control group. Bone metastatic lesions were significantly reduced by this combined therapy compared with conventional therapy. The adverse reactions and skeletal-related events (SREs) in the observational group were significantly lower than that in the control group.
Overall it can be concluded from the study that the application of zoledronic acid combined with calcitonin was significantly more effective for bone metastasis and osteoporosis in patients with lung cancer, compared with conventional therapy.
Written by: Rabeeia
Your email address will not be published. Required fields are marked *
17 November, 2019